Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...

The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells ...

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

Moderna and Merck said on Wednesday (August 19) that a personalized mRNA cancer vaccine reduced the risk of recurrence and ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...